SAAG ≥ 1.1 g/dL
Indicates Portal Hypertension (cirrhosis, right heart failure, Budd-Chiari); SAAG < 1.1 g/dL indicates peritoneal carcinomatosis, TB, pancreatitis, or nephrotic syndrome.
SBP Diagnosis & Rx
Ascitic fluid PMNs ≥ 250 cells/mm3 → immediate IV Ceftriaxone + IV Albumin (1.5 g/kg day 1, 1.0 g/kg day 3 to prevent HRS). Secondary prophylaxis: Norfloxacin/Ciprofloxacin or TMP-SMX.
Acute Variceal Hemorrhage
Restrictive transfusion (target Hgb 7–9 g/dL), IV Octreotide + IV Ceftriaxone, and emergent EGD variceal band ligation within 12 hours.
Hepatic Encephalopathy
Asterixis + hyperammonemia; treat precipitant (GI bleed, SBP, hypokalemia) + Lactulose (acidifies colon, trapping NH3 as NH4+) + Rifaximin.
Hepatorenal Syndrome
Splanchnic vasodilation + extreme renal cortical vasoconstriction (FeNa < 1%, urine Na < 10, bland sediment, no response to albumin challenge); Rx: Octreotide + Midodrine + Albumin (or Terlipressin/Norepinephrine).
Hemochromatosis vs. Wilson
Hemochromatosis: HFE C282Y, transferrin sat > 45%, bronze diabetes, phlebotomy. Wilson: ATP7B, low ceruloplasmin, Kayser-Fleischer rings, penicillamine/trientine/zinc.
HCC Surveillance
All cirrhotic patients (and high-risk chronic HBV carriers) require RUQ Ultrasound ± serum Alpha-Fetoprotein (AFP) every 6 months.
Hepatic Autonomics
Sympathetics: T5–T9 (right greater splanchnic / celiac ganglion); Parasympathetics: Vagus (CN X); Anterior Chapman: Right 5th–6th ICS.
Ascites Evaluation & The Serum-Ascites Albumin Gradient (SAAG)
Diagnostic paracentesis is mandatory for all patients with new-onset ascites or cirrhotic patients hospitalized with clinical deterioration. Calculate SAAG = Serum Albumin − Ascitic Fluid Albumin:
| SAAG Level | Pathophysiologic Mechanism | Etiologies |
|---|---|---|
| High Gradient (≥ 1.1 g/dL) | Increased hydrostatic pressure in portal microcirculation (Portal HTN) | Cirrhosis, Congestive Heart Failure, Constrictive Pericarditis, Budd-Chiari syndrome |
| Low Gradient (< 1.1 g/dL) | Increased peritoneal capillary permeability or non-portal peritoneal pathology | Peritoneal Carcinomatosis, Peritoneal Tuberculosis, Pancreatic Ascites, Nephrotic Syndrome |
Calculating the Serum-Ascites Albumin Gradient (SAAG) & Ascitic Total Protein
Diagnostic evaluation of new-onset ascites begins with an abdominal paracentesis to calculate the Serum-Ascites Albumin Gradient (SAAG) = Serum Albumin minus Ascitic Fluid Albumin (drawn on the same day; superior to the obsolete exudate/transudate ratio because SAAG directly reflects hydrostatic portal pressure): a SAAG ≥1.1 g/dL confirms Portal Hypertension with 97% accuracy, whereas a SAAG <1.1 g/dL indicates non-portal peritoneal pathology (peritoneal carcinomatosis, tuberculous peritonitis, pancreatitis, serositis/lupus, or nephrotic syndrome). Pairing the SAAG with the Ascitic Fluid Total Protein further subdivides high-SAAG (≥1.1 g/dL) ascites: Ascitic Protein <2.5 g/dL indicates sinusoidal portal hypertension from hepatic cirrhosis (fibrotic capillarization of hepatic sinusoids prevents protein leakage into the space of Disse), whereas SAAG ≥1.1 g/dL WITH Ascitic Protein ≥2.5 g/dL indicates post-sinusoidal venous congestion with intact permeable hepatic sinusoids—classic for Right-Sided Congestive Heart Failure, Constrictive Pericarditis, or Budd-Chiari Syndrome (hepatic vein thrombosis).
Diuretic Ratio (100:40 Spironolactone to Furosemide) & Large-Volume Paracentesis Albumin Rule
First-line medical management of cirrhotic ascites consists of dietary sodium restriction (<2 g/day; fluid restriction is NOT indicated unless serum Na+ drops below 120–125 mEq/L) combined with dual oral diuretics in a strict 100 mg : 40 mg ratio of Spironolactone to Furosemide (titrated upward in tandem up to 400 mg : 160 mg/day to achieve 0.5 kg/day weight loss without peripheral edema or 1.0 kg/day with edema). Because hyperaldosteronism is the primary driver of distal renal sodium retention in cirrhosis, spironolactone is the cornerstone agent, while furosemide balances potassium homeostasis to maintain normokalemia. For tense or refractory ascites requiring a Large-Volume Paracentesis (LVP) removing >5 liters of fluid, always administer 6 to 8 grams of intravenous 25% Albumin per liter of ascitic fluid removed to prevent post-paracentesis circulatory dysfunction, hepatorenal syndrome, and mortality.
Spontaneous Bacterial Peritonitis (SBP) Protocol
SBP is an acute bacterial infection of ascitic fluid without an intra-abdominal surgically treatable source. Pathogens are predominantly enteric gram-negative bacilli (E. coli, Klebsiella) or streptococci.
- Diagnostic Criterion: Ascitic neutrophil count (PMNs) ≥ 250 cells/mm3 (0.25 × 109/L).
- First-Line Therapy: IV Ceftriaxone 2 g/day or Cefotaxime 2 g q8h for 5 days.
- IV Albumin Infusion: 1.5 g/kg on day 1, followed by 1.0 g/kg on day 3. Reduces the incidence of hepatorenal syndrome and improves survival by over 50%.
| Clinical Phase | Diagnostic / Therapeutic Threshold | First-Line Regimen | Mortality & Hepatorenal Prevention Pearl |
|---|---|---|---|
| Diagnostic Paracentesis | Ascitic fluid Absolute Polymorphonuclear (PMN / neutrophil) count >= 250 cells/mm3 | Perform bedside paracentesis BEFORE starting antibiotics in any cirrhotic admitted with fever, abdominal pain, encephalopathy, GI bleed, or AKI | SAAG >= 1.1 g/dL + Ascitic Total Protein < 2.5 g/dL confirms cirrhotic portal hypertension; polymicrobial flora or glucose <50 + LDH > ULN + protein >1 g/dL suggests secondary peritonitis (perforation) |
| Empiric Acute Therapy | Initiate immediately when ascitic PMN >= 250 cells/mm3 (even if Gram stain/culture pending) | 3rd-Generation IV Cephalosporin: Ceftriaxone (2 g IV daily) or Cefotaxime (2 g IV q8h) for 5 days | Covers enteric Gram-negative bacilli (E. coli, Klebsiella pneumoniae) and Streptococcus species |
| Albumin Co-Administration | Mandatory if baseline serum Cr > 1.0 mg/dL, BUN > 30 mg/dL, or Total Bilirubin > 4.0 mg/dL | IV 25% Albumin: 1.5 g/kg on Day 1, followed by 1.0 g/kg on Day 3 | Reduces incidence of Type 1 Hepatorenal Syndrome (HRS-AKI) and cuts inpatient mortality by >60% |
| Secondary & Primary Prophylaxis | All prior SBP survivors; cirrhotic GI bleeders; or ascitic total protein < 1.5 g/dL with severe liver/renal dysfunction | Oral Norfloxacin (400 mg daily), Ciprofloxacin (500 mg daily), or TMP-SMX DS daily (Ceftriaxone IV x 7d during acute GI bleed) | Discontinue non-selective beta-blockers permanently after an episode of SBP complicated by hypotension or HRS |
Pathogenesis of Bacterial Translocation & Secondary Peritonitis (Runyon Criteria)
Spontaneous Bacterial Peritonitis (SBP) develops when portal hypertension causes intestinal mucosal edema and delayed gut transit, allowing enteric bacteria—most commonly Escherichia coli, Klebsiella pneumoniae, and Streptococcus pneumoniae—to translocate across the intestinal wall into mesenteric lymph nodes, enter the systemic circulation, and seed low-complement, low-opsonin (<1.5 g/dL protein) ascitic fluid. While monomicrobial SBP is treated medically with a 5-day course of IV Ceftriaxone (2 g daily) plus IV Albumin (1.5 g/kg Day 1, 1.0 g/kg Day 3) and surgery is contraindicated, the clinician must never miss Secondary Bacterial Peritonitis (from a perforated peptic ulcer, appendicitis, or diverticulitis into ascitic fluid). Suspect Secondary Bacterial Peritonitis—and obtain an emergent abdominal CT with surgical consultation—if ascitic fluid culture grows polymicrobial / anaerobic flora or meets ≥2 of Runyon criteria: Ascitic Total Protein >1.0 g/dL, Glucose <50 mg/dL, and LDH > upper limit of normal for serum.
Hepatic Encephalopathy Triggers (TIPS, Hypokalemia, Alkalosis) & Lactulose/Rifaximin Mechanism
SBP, variceal GI bleeding, constipation, infection, sedatives, TIPS placement, and diuretic-induced hypokalemia and metabolic alkalosis are the classic precipitants of Hepatic Encephalopathy (HE) (presenting with reversal of sleep-wake cycle, asterixis ['flapping tremor'], hyperreflexia, and confusion/coma). Hypokalemia and metabolic alkalosis are particularly dangerous in cirrhosis: hypokalemia stimulates proximal renal tubular glutaminase (increasing renal ammonia production), while alkalosis (high pH) shifts the equilibrium from charged, membrane-impermeable ammonium (NH4+) to uncharged, lipid-soluble ammonia gas (NH3), which freely crosses the blood-brain barrier where astrocytes convert it into osmotically active glutamine, causing astrocyte swelling and cerebral edema. First-line therapy corrects the precipitant and administers oral/rectal Lactulose (a non-absorbable disaccharide fermented by colonic bacteria into lactic and acetic acids, lowering colonic pH to trap NH3 as non-absorbable NH4+ excreted in 2–3 soft stools/day) plus Rifaximin (a non-absorbable oral rifamycin that eradicates urease-producing gut flora).
Pathophysiology of Portal Hypertension, Portosystemic Anastomoses & Child-Pugh / MELD-Na Scoring
Cirrhosis represents the irreversible histological end-stage of chronic hepatic inflammation, defined by bridging fibrous septa and parenchymal regenerative nodules that distort normal lobular architecture. Under injury from alcohol, viral hepatitis (HBV/HCV), or metabolic dysfunction-associated steatohepatitis (MASH), quiescent vitamin A-storing hepatic stellate (Ito) cells within the Space of Disse are activated by TGF-β and PDGF into myofibroblasts that deposit dense Type I and III collagen, obliterating sinusoidal fenestrations ('capillarization of sinusoids'). Combined with intrahepatic endothelial nitric oxide (NO) deficiency and excess endothelin-1, intrahepatic vascular resistance surges, elevating the Hepatic Venous Pressure Gradient (HVPG > 5 mmHg defines portal hypertension; ≥ 10 mmHg causes varices; ≥ 12 mmHg causes variceal hemorrhage). Paradoxically, the splanchnic arterial bed undergoes massive NO-mediated vasodilation, creating systemic effective arterial underfilling that activates RAAS, sympathetic tone, and ADH—driving relentless sodium/water retention and hyperdynamic circulation.
| Anatomical Anastomosis Site | Portal Venous Tributary | Systemic Venous Tributary | Clinical Manifestation & Board Significance |
|---|---|---|---|
| Distal Esophagus & Gastric Cardia | Left Gastric (Coronary) Vein & Short Gastric Veins | Azygos & Hemiazygos Veins (draining into SVC) | Esophageal and Gastric Fundal Varices — submucosal venous plexuses with highest risk of fatal upper GI hemorrhage |
| Anterior Abdominal Wall (Umbilicus) | Paraumbilical Veins (running along ligamentum teres) | Superior & Inferior Epigastric Veins (via superficial thoracoepigastric veins) | Caput Medusae (dilated tortuous periumbilical veins radiating outward from the umbilicus) & Cruveilhier-Baumgarten venous hum |
| Anorectal Junction (Above/Below Pectinate Line) | Superior Rectal (Hemorrhoidal) Vein (via inferior mesenteric vein) | Middle & Inferior Rectal Veins (draining into internal iliac / pudendal veins) | Anorectal Varices (distinct from simple prolapsed cushions, may cause painless hematochezia) |
| Retroperitoneum & Spleen | Colic, Splenic, and Omental Veins (Retzius veins) | Renal, Lumbar, Phrenic, and Gonadal Veins | Spontaneous splenorenal shunts (contribute to chronic refractory hepatic encephalopathy by bypassing hepatic first-pass clearance) |
| Prehepatic vs. Posthepatic Portal HTN | Prehepatic: Portal Vein Thrombosis (normal SAAG/liver histology). Posthepatic: Budd-Chiari Syndrome (hepatic vein thrombosis) | Budd-Chiari associations: Polycythemia Vera (JAK2 V617F), PNH, OCPs, Pregnancy, HCC | Budd-Chiari presents with acute triad: Painful hepatomegaly, sudden ascites, and hepatic failure with caudate lobe hypertrophy (drains directly into IVC) |
Child-Pugh Score (5 Parameters: ABCDE) & Surgical Mortality
The Child-Pugh classification stratifies cirrhosis severity and perioperative mortality using five clinical and laboratory parameters (mnemonic ABCDE, each scored 1–3 points): Albumin (> 3.5, 2.8–3.5, < 2.8 g/dL), Bilirubin (< 2, 2–3, > 3 mg/dL), Clotting / INR (< 1.7, 1.7–2.3, > 2.3), Distension / Ascites (none, mild/diuretic-controlled, moderate-severe/refractory), and Encephalopathy (none, Grade I–II, Grade III–IV). Class A (5–6 pts) denotes compensated cirrhosis (~10% abdominal surgery mortality); Class B (7–9 pts) denotes significant functional compromise (~30% surgical mortality); and Class C (10–15 pts) denotes decompensated cirrhosis (> 75–80% surgical mortality—elective surgery is strictly contraindicated!).
MELD-Na Score & Orthotopic Liver Transplant Allocation
While Child-Pugh includes subjective clinical assessments (ascites and encephalopathy), the MELD-Na (Model for End-Stage Liver Disease) score uses four objective laboratory values to predict 90-day mortality and prioritize organ allocation on the orthotopic liver transplant waitlist: Serum Bilirubin, INR, Serum Creatinine, and Serum Sodium (MELD 3.0 also incorporates Serum Albumin and sex). A MELD-Na score ≥ 15 generally marks the threshold where liver transplantation survival benefit exceeds transplant risk. Standard MELD exception points are awarded for conditions like Stage T2 Hepatocellular Carcinoma within the Milan Criteria (1 lesion ≤ 5 cm, or up to 3 lesions each ≤ 3 cm, with no vascular invasion or extrahepatic metastasis) or hepatopulmonary syndrome.
Ascites Diuretic Ratio (Spironolactone : Furosemide = 100 : 40 mg)
First-line medical management of cirrhotic ascites (SAAG ≥ 1.1 g/dL with ascitic total protein < 2.5 g/dL) requires dietary sodium restriction (≤ 2,000 mg/day; fluid restriction is ONLY indicated if serum sodium drops < 125 mEq/L!) combined with dual oral diuretic therapy in a strict 100 mg Spironolactone to 40 mg Furosemide ratio, titrated every 3–5 days up to a maximum of 400 mg spironolactone / 160 mg furosemide daily. Because secondary hyperaldosteronism drives distal tubular sodium retention in cirrhosis, aldosterone antagonism with spironolactone is more effective than loop diuretics alone, and the 100:40 ratio maintains normokalemia.
Acute Variceal Hemorrhage Resuscitation, Prophylaxis & TIPS Complications
Esophageal and gastric varices develop in 50% of cirrhotic patients and bleed at a rate of 10–15% per year, carrying a 15–20% mortality per bleeding episode. Every patient newly diagnosed with cirrhosis must undergo a screening upper endoscopy (EGD) (unless non-invasive transient elastography liver stiffness is < 20 kPa and platelet count is > 150,000/μL). Primary prophylaxis to prevent a first variceal bleed in patients with medium-to-large varices (or small varices with high-risk red wale markings or Child-Pugh C disease) consists of either a non-selective beta-blocker (Propranolol, Nadolol, or Carvedilol)—which blocks β1 receptors (reducing cardiac output) and β2 splanchnic vasodilatory receptors (leaving unopposed α1-mediated mesenteric arteriolar vasoconstriction to reduce portal inflow)—OR endoscopic variceal band ligation (EVL).
| Intervention / Stage | Specific Regimen & Modality | Mechanism of Action | Clinical Indications & Contraindications |
|---|---|---|---|
| Acute Variceal Bleed Vasoactive Drug | IV Octreotide (50 mcg bolus, then 50 mcg/hr x 3-5 days) or Terlipressin | Somatostatin analog inhibits glucagon-mediated splanchnic vasodilation -> splanchnic vasoconstriction reduces portal venous inflow and pressure | Start immediately upon presentation BEFORE endoscopy alongside restrictive pRBC transfusion (transfuse at Hgb <7 g/dL, target 7-9 g/dL; overtransfusion spikes portal pressure!) |
| Acute Antibiotic Prophylaxis | IV Ceftriaxone 1 g daily x 7 days (or oral Fluoroquinolone step-down) | Prevents bacterial translocation across edematous gut mucosa during variceal hemorrhage | Proven to independently reduce rebleeding, SBP/bacteremia, and inpatient mortality in all cirrhotic GI bleeds (even without ascites) |
| Definitive Endoscopic Therapy | Urgent Upper Endoscopy (EGD) with Endoscopic Variceal Band Ligation (EVL) within <=12 hours | Mechanical rubber-band strangulation and thrombosis of distal esophageal variceal columns (cyanoacrylate glue for isolated gastric fundal varices) | Perform endotracheal intubation prior to EGD if massive hematemesis or hepatic encephalopathy to prevent aspiration |
| TIPS (Transjugular Intrahepatic Portosystemic Shunt) | Interventional radiology expandable stent connecting a Hepatic Vein branch directly to a Portal Vein branch | Bypasses high-resistance cirrhotic sinusoids to decompress portal hypertension | Indicated for refractory variceal bleeding or refractory ascites. Major complication: Hepatic Encephalopathy (30-40%, blood bypasses hepatic urea cycle). Contraindicated in severe heart failure/pulmonary hypertension, severe encephalopathy, or polycystic liver disease |
| Primary & Secondary Prophylaxis | Primary: Non-Selective Beta-Blocker (Propranolol, Nadolol, or Carvedilol) OR EVL. Secondary (post-bleed): NSBB + Serial EVL | Beta-1 blockade reduces cardiac output; Beta-2 blockade allows unopposed alpha-1 splanchnic vasoconstriction, lowering portal venous inflow | Both NSBBs AND serial EVL are required together for secondary prophylaxis after a prior variceal bleed |
Step-by-Step Acute Esophageal Variceal Bleed Resuscitation
When a cirrhotic patient presents with hematemesis or melena, execute the five-step acute variceal hemorrhage bundle simultaneously: (1) Airway protection (elective endotracheal intubation prior to EGD if massive hematemesis or severe hepatic encephalopathy is present to prevent aspiration pneumonia) + two large-bore IV lines; (2) Restrictive RBC transfusion strategy (transfuse ONLY when Hgb < 7 g/dL, targeting 7–9 g/dL, to prevent portal pressure rebound); (3) Immediate vasoactive splanchnic vasoconstrictor infusion: IV Octreotide (somatostatin analogue that inhibits glucagon/VIP-mediated splanchnic vasodilation; 50 μg bolus then 50 μg/hr for 3–5 days) or Terlipressin; (4) Immediate empiric antibiotic prophylaxis with IV Ceftriaxone 1 g/day for 7 days (proven to reduce bacterial translocation/SBP, prevent re-bleeding, and decrease overall mortality!); and (5) Emergent upper endoscopy (EGD) with variceal band ligation within 12 hours.
Refractory Variceal Bleeding: Balloon Tamponade & TIPS
If massive variceal bleeding cannot be controlled endoscopically, temporary balloon tamponade (Sengstaken-Blakemore or Minnesota tube) or a self-expanding esophageal metal stent can be placed for up to 24 hours (mandatory endotracheal intubation is required before balloon placement, and the gastric balloon must never be inflated inside the esophagus due to Boerhaave rupture risk) as a bridge to definitive Transjugular Intrahepatic Portosystemic Shunt (TIPS) within 72 hours. For isolated gastric fundal varices (often caused by splenic vein thrombosis from pancreatitis—'left-sided portal hypertension', cured by splenectomy), endoscopic cyanoacrylate glue injection or TIPS is preferred over standard band ligation.
TIPS Mechanism, Indications, Contraindications & Encephalopathy Risk
A Transjugular Intrahepatic Portosystemic Shunt (TIPS) is an interventional radiology procedure that places an expandable metal stent through the liver parenchyma directly connecting a branch of the portal vein to a hepatic vein, bypassing the high-resistance cirrhotic sinusoids. Primary indications are refractory variceal hemorrhage and diuretic-refractory ascites / hepatic hydrothorax. Because TIPS shunts ammonia-rich splanchnic blood directly into the systemic vena cava without hepatic urea-cycle detoxification, the #1 major complication of TIPS is new or worsened Hepatic Encephalopathy (occurring in 30–50% of patients)! Absolute contraindications to TIPS include severe preexisting hepatic encephalopathy, severe right-sided heart failure or severe pulmonary hypertension (shunting splanchnic blood acutely overwhelms the right ventricle), polycystic liver disease, and active systemic sepsis. Secondary prophylaxis after surviving a variceal bleed requires BOTH a non-selective beta-blocker AND serial endoscopic band ligation.
Hepatic Encephalopathy, Hepatorenal Syndrome & Hepatopulmonary Syndromes
Decompensated cirrhosis produces multi-organ functional failure driven by portosystemic shunting of neurotoxins and extreme splanchnic-systemic hemodynamic mismatch. Hepatic encephalopathy (HE) represents a reversible neuropsychiatric spectrum triggered by gut-derived nitrogenous toxins—primarily ammonia (NH3) produced by colonic bacterial urease and small intestinal glutaminase, alongside mercaptans and GABAergic neurosteroids—that bypass the cirrhotic liver and cross the blood-brain barrier. Within cerebral astrocytes, glutamine synthetase converts glutamate and ammonia into osmotically active glutamine, causing astrocyte swelling, cerebral edema, oxidative stress, and GABAergic inhibition. Clinical progression spans West Haven Grades I–IV: Grade I (sleep-wake reversal: day sleeping/night insomnia, subtle euphoria/inattention), Grade II (lethargy, disorientation to time, personality changes, and classic asterixis ['flapping tremor'—negative myoclonus upon wrist dorsiflexion]), Grade III (somnolence/stupor, gross confusion, hyperreflexia), and Grade IV (coma).
| Complication | Pathophysiological Mechanism | Diagnostic Criteria & Findings | Definitive Medical & Surgical Management |
|---|---|---|---|
| Hepatic Encephalopathy (HE) | Portosystemic shunting + defective urea cycle → hyperammonemia → astrocyte glutamine accumulation & swelling | Clinical diagnosis (do NOT rely on serial venous ammonia levels to titrate therapy!); asterixis, sleep reversal, confusion | 1. Identify/treat precipitant; 2. Lactulose (titrated to 2–3 soft stools/day); 3. Add Rifaximin 550 mg BID for recurrent episodes |
| Hepatorenal Syndrome (HRS-AKI) | Extreme NO-mediated splanchnic vasodilation → severe arterial underfilling → intense RAAS/sympathetic renal cortical vasoconstriction with structurally normal kidneys | Cirrhosis + ascites + AKI (FeNa < 1%, urine Na < 10 mEq/L, bland sediment, no proteinuria) that fails to improve after 48 hours of diuretic withdrawal + IV Albumin (1 g/kg/day) | Splanchnic vasoconstrictor + Albumin: IV Terlipressin + Albumin, IV Norepinephrine + Albumin (ICU), or Octreotide + Midodrine + Albumin. Definitive cure: Liver Transplantation |
| Hepatopulmonary Syndrome (HPS) | Excess hepatic/pulmonary nitric oxide (NO) and endothelin-1 cause intrapulmonary microvascular dilations at lung bases → intrapulmonary right-to-left shunting (V/Q mismatch) | Platypnea (dyspnea worsens when sitting upright, improves supine) & Orthodeoxia (O2 sat drops ≥ 5% upright); contrast echo shows bubbles in LA after 3–6 cardiac cycles | Supplemental oxygen; Liver Transplantation is curative (patients receive MELD exception points if PaO2 < 60 mmHg) |
| Portopulmonary Hypertension (POPH) | Humoral vasoconstrictors (endothelin-1, serotonin) bypass liver via shunts and induce pulmonary arterial medial hypertrophy and plexiform fibrosis | Exertional dyspnea, loud P2, RV heave, tricuspid regurgitation; Right Heart Catheterization shows mPAP > 20 mmHg, PVR ≥ 3 Wood units, PCWP ≤ 15 mmHg | Pulmonary vasodilators (epoprostenol, bosentan, sildenafil); severe POPH (mPAP > 45–50 mmHg) is an absolute contraindication to liver transplant until pressures are lowered |
| Hepatic Hydrothorax | Ascitic fluid passes directly into pleural space (85% right-sided) through congenital microscopic defects in the tendinous diaphragm | Transudative pleural effusion; dyspneic cirrhotic patient | Sodium restriction + Spironolactone/Furosemide + therapeutic thoracentesis + TIPS (NEVER place a chronic chest tube—causes massive protein/electrolyte depletion and infection!) |
Interactive 2K Master Atlas Plate
Triggers of Hepatic Encephalopathy & Lactulose + Rifaximin Pharmacology
Over 80% of acute hepatic encephalopathy episodes are precipitated by a reversible clinical trigger that must be actively sought and corrected: (1) Gastrointestinal bleeding (blood in the gut provides a massive protein/hemoglobin load for bacterial ammoniagenesis), (2) Infection (especially SBP or UTI), (3) Hypokalemia and metabolic alkalosis (from aggressive loop/thiazide diuresis, vomiting, or diarrhea), (4) Constipation, (5) Sedative medications (benzodiazepines, opioids, antihistamines), and (6) Recent TIPS placement or portal vein thrombosis. Lactulose is a non-absorbable synthetic disaccharide metabolized by colonic bacteria into lactic and acetic acids; this lowers colonic luminal pH, protonating diffusible ammonia (NH3) into charged, non-absorbable ammonium ions (NH4+) that are excreted via osmotic catharsis. Rifaximin is a non-absorbable oral rifamycin antibiotic that eradicates urease-producing gut flora.
Differentiating Hepatorenal Syndrome from Prerenal Azotemia & ATN
Both Prerenal Azotemia and Hepatorenal Syndrome (HRS) present with FeNa < 1%, urine sodium < 10–20 mEq/L, and a bland urine sediment (whereas Acute Tubular Necrosis [ATN] exhibits FeNa > 2% and muddy brown granular casts). Therefore, HRS is a diagnosis of exclusion made ONLY after performing a mandatory 48-hour diagnostic volume challenge: withhold all diuretics and infuse IV 25% Albumin (1 g/kg/day, max 100 g/day) for 2 consecutive days while ruling out shock, nephrotoxic drugs (NSAIDs, aminoglycosides), and hydronephrosis on renal ultrasound. If serum creatinine normalizes, the diagnosis is simple prerenal azotemia; if creatinine fails to improve despite 48 hours of albumin expansion, HRS-AKI is confirmed and treated with splanchnic vasoconstrictors (Terlipressin, Norepinephrine, or Midodrine + Octreotide) plus Albumin.
Hereditary & Metabolic Cirrhosis Differential and Hepatocellular Carcinoma (HCC)
When evaluating chronic transaminitis or newly diagnosed cirrhosis, pattern recognition of liver chemistries and hereditary metabolic stigmata pinpoints the etiology. In most chronic hepatocellular diseases (viral hepatitis, MASH, autoimmune hepatitis, hemochromatosis, Wilson disease), ALT exceeds AST (AST:ALT ratio < 1) because ALT is purely cytosolic whereas AST is predominantly mitochondrial. The two classic exceptions where AST exceeds ALT are Alcoholic Hepatitis (AST:ALT ratio ≥ 2:1, because alcohol induces mitochondrial damage and depletes pyridoxal-5'-phosphate [Vitamin B6], which is required more heavily for ALT synthesis than AST; absolute AST/ALT values are virtually always < 300–500 IU/L—values > 1,000 IU/L indicate ischemic 'shock' liver, acetaminophen toxicity, or acute viral/autoimmune hepatitis!) and advanced cirrhosis of any cause.
| Disorder | Genetics & Molecular Defect | Extrahepatic Clinical Stigmata | Diagnostic Confirmatory Tests & Histopathology | First-Line Therapy |
|---|---|---|---|---|
| Hereditary Hemochromatosis | Autosomal recessive HFE gene C282Y (or H63D) mutation on Chromosome 6 (linked to HLA-A3) → LOW Hepcidin → uninhibited ferroportin intestinal iron absorption | 'Bronze Diabetes' triad: Micronodular cirrhosis, skin hyperpigmentation, and diabetes mellitus; plus restrictive/dilated cardiomyopathy, secondary hypogonadism, and 2nd/3rd MCP arthropathy (pseudogout / CPPD); susceptibility to Vibrio vulnificus, Yersinia, Listeria | Initial screen: Transferrin Saturation > 45% and Ferritin > 200–300 ng/mL → HFE genetic testing; Liver biopsy shows Prussian blue-positive hemosiderin in periportal hepatocytes | Serial Therapeutic Phlebotomy (weekly until ferritin 50–100 ng/mL); iron chelators (Deferasirox, Deferoxamine) if anemic or unstable |
| Wilson Disease (Hepatolenticular Degeneration) | Autosomal recessive ATP7B gene mutation on Chromosome 13 (hepatocyte P-type ATPase copper transporter) → impaired biliary copper excretion and impaired incorporation of copper into apoceruloplasmin (presents age 5–35) | Kayser-Fleischer rings (golden-brown copper deposits in Descemet membrane of cornea on slit-lamp exam); basal ganglia (putamen) degeneration (parkinsonian tremor, dysarthria, dystonia, wing-beating tremor, psychosis); Coombs-negative hemolytic anemia & Fanconi RTA | LOW serum Ceruloplasmin (< 20 mg/dL), HIGH 24-hour urinary copper excretion (> 100 μg/24h), and hepatic copper quantification > 250 μg/g dry weight (Rhodanine or rubeanic acid stain) | Copper chelators: D-Penicillamine (supplement with Vitamin B6) or Trientine (fewer side effects) + Oral Zinc (induces enterocyte metallothionein to block gut copper absorption) |
| Alpha-1 Antitrypsin (AAT) Deficiency | Autosomal codominant SERPINA1 mutation on Chromosome 14; PiZZ genotype causes misfolded AAT polymerization inside hepatocyte endoplasmic reticulum | Panacinar emphysema (lower lung lobes in young non-smokers due to uninhibited neutrophil elastase) + neonatal cholestasis / adult cirrhosis + necrotizing panniculitis | Low serum AAT level + PiZZ phenotyping; Liver biopsy shows pink, PAS-positive, diastase-resistant intracytoplasmic globules in periportal hepatocytes | Smoking cessation, pooled human AAT augmentation therapy for lung disease; liver transplantation cures the hepatic defect (donor liver secretes normal PiMM AAT!) |
| Autoimmune Hepatitis (AIH) | T-cell-mediated hepatocyte destruction in young/middle-aged women; HLA-DR3 / HLA-DR4 | Concurrent autoimmune disorders (Hashimoto, Sjögren, celiac, UC); marked hypergammaglobulinemia (elevated serum IgG) | Type 1: ANA and Anti-Smooth Muscle Antibody (ASMA). Type 2 (pediatric): Anti-LKM-1. Biopsy: interface hepatitis (piecemeal necrosis) with dense plasma cell infiltrate | Induction with Prednisone followed by steroid-sparing maintenance with Azathioprine (check TPMT genotype first!) |
Hepatocellular Carcinoma (HCC) Surveillance & Non-Biopsy Radiographic Diagnosis
Chronic cirrhosis (from HBV, HCV, alcohol, MASH, or hemochromatosis) and non-cirrhotic chronic Hepatitis B infection (due to direct HBV DNA integration into host oncogenes) confer a high lifetime risk of Hepatocellular Carcinoma (HCC). Mandatory surveillance requires Right Upper Quadrant Ultrasound with or without serum Alpha-Fetoprotein (AFP) every 6 months. Suspect HCC whenever a previously stable cirrhotic patient develops an unexplained right upper quadrant mass, weight loss, bloody ascites, portal vein thrombosis, or paraneoplastic syndromes (erythrocytosis from ectopic EPO, hypoglycemia from IGF-2, hypercalcemia from PTHrP). If a screening ultrasound identifies a nodule ≥ 1 cm, the confirmatory test is a 4-phase multidetector contrast CT or dynamic contrast MRI: because HCC is supplied exclusively by the hepatic artery whereas normal parenchyma is supplied 75% by the portal vein, a lesion demonstrating arterial-phase hyperenhancement followed by portal-venous/delayed-phase 'washout' (LI-RADS 5) is 100% diagnostic of HCC WITHOUT performing a liver biopsy!
HCC Treatment Stratification: Resection, Transplant (Milan Criteria), TACE & Systemic Therapy
Management of HCC depends on hepatic functional reserve (Child-Pugh class) and tumor burden: (1) Non-cirrhotic or compensated Child-Pugh A patients with a solitary resectable tumor and no portal hypertension undergo surgical partial hepatectomy; (2) Decompensated cirrhotics or those with portal hypertension whose tumors fall within the Milan Criteria (1 lesion ≤ 5 cm, OR 2–3 lesions each ≤ 3 cm, without macrovascular invasion or extrahepatic spread) undergo curative Orthotopic Liver Transplantation (or radiofrequency ablation); (3) Intermediate-stage unresectable liver-confined tumors receive locoregional Transarterial Chemoembolization (TACE) or Yttrium-90 radioembolization; and (4) Advanced/metastatic HCC or tumors with portal vein invasion receive systemic immunotherapy (Atezolizumab + Bevacizumab or multikinase inhibitors Sorafenib / Lenvatinib).
Primary Biliary Cholangitis (PBC) vs. Primary Sclerosing Cholangitis (PSC)
Two autoimmune cholestatic liver diseases progress to biliary cirrhosis: Primary Biliary Cholangitis (PBC) predominantly affects middle-aged women (9:1 female predominance) with autoimmune destruction of intrahepatic bile ducts (florid duct lesions), presenting with pruritus, fatigue, xanthelasmas, elevated Alkaline Phosphatase, and Anti-Mitochondrial Antibodies (AMA, > 95%); first-line therapy is Ursodeoxycholic acid (UDCA). Conversely, Primary Sclerosing Cholangitis (PSC) predominantly affects young men with Ulcerative Colitis (80% association) and involves concentric 'onion-skin' periductal fibrosis of BOTH intrahepatic and extrahepatic bile ducts, producing a classic 'beaded' appearance on MRCP/ERCP, positive p-ANCA, and a markedly elevated lifetime risk of Cholangiocarcinoma (CA 19-9) and gallbladder/colorectal cancer.
COMLEX / OMM Integration
NBOME High-Yield Correlate
Hepatic Autonomics, Splanchnic Hemodynamics & Lymphatic Drainage in Cirrhosis
- Sympathetic & Parasympathetic Innervation: Sympathetic preganglionic neurons to the liver and biliary tree originate at T5–T9 (predominantly right-sided), travel via the greater splanchnic nerve, and synapse in the celiac ganglion. Sympathetic tone regulates intrahepatic sinusoidal sphincter resistance and hepatic arterial vasoconstriction. Parasympathetic innervation derives from the vagus nerve (CN X). Referred pain from hepatic capsule distension travels via the right phrenic nerve (C3–C5) to the right shoulder and trapezius ridge.
- Chapman Reflexes & Counterstrain: Anterior Chapman reflex points for the liver are located in the right 5th and 6th intercostal spaces from the midclavicular line to the sternum (gallbladder sits solely at the right 6th ICS). Posterior Chapman points lie between the transverse processes of T5–T6 and T6–T7 on the right. Anterior thoracic counterstrain tenderpoints AT5–AT7 are treated with flexion and slight sidebending/rotation toward the tenderpoint.
- Lymphatic Drainage & OMT Contraindications: Because the liver produces 25% to 50% of all lymph flowing through the thoracic duct, portal hypertension overwhelms Space of Disse lymphatics, causing protein-rich fluid to weep directly across Glisson capsule into the peritoneal cavity as ascites. Gentle thoracic inlet myofascial release (Sibson fascia), diaphragmatic doming, and celiac ganglion inhibition reduce transdiaphragmatic resistance and support ascitic mobilization. Contraindications: Direct deep hepatic pump techniques or forceful rib compressions are contraindicated in patients with severe thrombocytopenia, coagulopathy (elevated INR), hepatocellular carcinoma, or acute variceal hemorrhage due to bleeding risk.
Board Traps & Common Distractors
- Trap: Continuing or initiating non-selective beta-blockers (propranolol, nadolol, carvedilol) during an acute esophageal variceal hemorrhage or in a patient with refractory ascites and spontaneous bacterial peritonitis (SBP). Beta-blockers blunt the compensatory tachycardic response to hemorrhagic shock and precipitate hepatorenal syndrome during SBP!
- Trap: Transfusing packed red blood cells to a 'normal' hemoglobin (> 10 g/dL) in a cirrhotic patient with an upper GI bleed. Over-transfusion acutely expands splanchnic intravascular volume and elevates portal venous pressure, triggering catastrophic re-bleeding from esophageal varices; strictly adhere to a restrictive transfusion threshold of Hgb > 7 g/dL (target 7–9 g/dL).
- Trap: Performing a large-volume paracentesis (> 5 Liters removed) without administering IV Albumin (6–8 g of albumin per liter of ascitic fluid removed). Omitting albumin triggers Post-Paracentesis Circulatory Dysfunction (PPCD), severe splanchnic vasodilation, hyponatremia, and acute hepatorenal syndrome.
- Trap: Restricting dietary protein in a patient with hepatic encephalopathy. Chronic cirrhotic patients suffer from profound sarcopenia, and skeletal muscle is the primary extrahepatic site for ammonia detoxification (via glutamine synthetase); protein restriction worsens muscle wasting and hyperammonemia!
- Trap: Relying on serum PT/INR to predict procedural bleeding risk (such as paracentesis) or administering routine prophylactic Fresh Frozen Plasma (FFP) before paracentesis in cirrhosis. Cirrhosis simultaneously decreases procoagulant factors (II, V, VII, IX, X) AND anticoagulant proteins (Protein C, Protein S, Antithrombin III) while increasing Factor VIII and vWF, creating a rebalanced hemostatic state; FFP only causes volume overload and portal pressure elevation.
- Trap: Ordering diagnostic liver biopsy to confirm Hepatocellular Carcinoma (HCC) when multiphase contrast CT/MRI shows classic arterial phase hyperenhancement with portal venous washout (LI-RADS 5). Cirrhotic HCC is diagnosed radiographically without biopsy to avoid needle-tract tumor seeding and hemorrhage!
- Trap: Missing hypokalemia and metabolic alkalosis (often from over-diuresis with furosemide) as the trigger for acute hepatic encephalopathy. Hypokalemia stimulates renal proximal tubular ammoniagenesis, while alkalosis converts charged ammonium (NH4+) into uncharged lipophilic ammonia (NH3) that freely crosses the blood-brain barrier.
Previous Chapter
•
Vol 2: Clinical Ch. 11
Thyroid Storm, Myxedema Coma & Adrenal Crisis
Vol 2: Clinical Ch. 13
•
Next Chapter
Inflammatory Bowel Disease
Table of Contents (105 Chapters)
Volume 2: Organ System Clinical Pathology • Chapter 12 of 60